Skip to content

Author

Guanghui Liang

We have 2 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

P1.083. Sequential Versus Concurrent Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized, Controlled, Open-Label, Phase II Trial

Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Neoadjuvant chemotherapy combined with PD-1 inhibitors has application potential for locally advanced esophageal squamous cell carcinoma (ESCC), but there is no prospective evidence for the optimal timing of the dose (sequential vs. concurrent)....

Yan Zheng, Jiwei Wu, Ling-Di Zhao et al. · 0 citations
Aug 2026

OA06-LBA01.4. A Multimodal Classifier to Stratify Response to Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on RCT-HCHTOG1909

The esophageal cancer multimodal immuno-chemotherapy classifier (EMIC), which effectively stratifies patients into two groups with distinct therapeutic responses: EMIC1 (predicted to benefit from combined immuno-chemotherapy) and EMIC2 (predicted to have equivalent outcomes with chemotherapy alone), providing a rationa...

Yan Zheng, Wen-Qun Xing, Ji Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.